JP2007530498A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530498A5
JP2007530498A5 JP2007504378A JP2007504378A JP2007530498A5 JP 2007530498 A5 JP2007530498 A5 JP 2007530498A5 JP 2007504378 A JP2007504378 A JP 2007504378A JP 2007504378 A JP2007504378 A JP 2007504378A JP 2007530498 A5 JP2007530498 A5 JP 2007530498A5
Authority
JP
Japan
Prior art keywords
weight
pharmaceutical composition
hydroxy tamoxifen
composition according
isomer form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007504378A
Other languages
English (en)
Other versions
JP2007530498A (ja
JP5489407B2 (ja
Filing date
Publication date
Priority claimed from US10/805,530 external-priority patent/US20050208139A1/en
Application filed filed Critical
Publication of JP2007530498A publication Critical patent/JP2007530498A/ja
Publication of JP2007530498A5 publication Critical patent/JP2007530498A5/ja
Application granted granted Critical
Publication of JP5489407B2 publication Critical patent/JP5489407B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (12)

  1. 約45%〜55%、約46%〜54%、約47%〜53%、約48%〜52%、約49%〜51%または約50%の4−ヒドロキシタモキシフェンがZ異性体の形態で存在し、残りの4−ヒドロキシタモキシフェンがE異性体の形態で存在する、4−ヒドロキシタモキシフェンを含む、平衡状態の医薬組成物。
  2. 経皮投与用に製剤されている請求項1に記載の医薬組成物。
  3. アルコールおよび/または浸透促進剤をさらに含む請求項2に記載の医薬組成物。
  4. 前記4−ヒドロキシタモキシフェンが、水性アルコールゲル、水性アルコール溶液、貼付剤、軟膏、クリーム、乳濁液(ローション)、散剤またはオイルに製剤されている請求項2に記載の医薬組成物。
  5. 前記4−ヒドロキシタモキシフェンが、水性アルコールゲルに製剤されている請求項4に記載の医薬組成物。
  6. 前記水性アルコールゲルが、エタノール、ミリスチン酸イソプロピル、およびヒドロキシプロピルセルロースを含む請求項5に記載の医薬組成物。
  7. この医薬組成物が、
    a)約0.01重量%〜0.2重量%の4−ヒドロキシタモキシフェン、
    b)約0.5重量%〜2重量%のミリスチン酸イソプロピル、
    c)約60重量%〜75重量%の無水アルコール、
    d)約25重量%〜40重量%の水系媒体、
    e)約0.5重量%〜5重量%のゲル化剤
    を含み;
    成分の前記パーセントが、前記組成物の重量に対する重量である請求項2に記載の医薬組成物。
  8. 単位用量小袋内または計量ポンプ付きの複数用量容器内に入れられている請求項7に記載の医薬組成物。
  9. (i)所定量の4−ヒドロキシタモキシフェンを準備する工程と、
    (ii)少なくとも1種の賦形剤を準備する工程と、
    (iii)前記4−ヒドロキシタモキシフェンと前記少なくとも1種の賦形剤とを組み合わせることにより、医薬組成物を形成する工程と、
    (iv)前記医薬組成物を、約45%〜55%、約46%〜54%、約47%〜53%、約48%〜52%、約49%〜51%または約50%の4−ヒドロキシタモキシフェンがZ異性体の形態で存在し、残りの4−ヒドロキシタモキシフェンがE異性体の形態で存在する平衡状態にする工程と
    を有する医薬組成物を製造する方法。
  10. 前記医薬組成物が経皮投与用のものである請求項9に記載の方法。
  11. 前記医薬組成物が、
    a)約0.01重量%〜0.2重量%の4−ヒドロキシタモキシフェン、
    b)約0.5重量%〜2重量%のミリスチン酸イソプロピル、
    c)約60重量%〜75重量%の無水アルコール、
    d)約25重量%〜40重量%の水系媒体、
    e)約0.5重量%〜5重量%のゲル化剤
    を含み;
    成分の前記パーセントが、前記組成物の重量に対する重量である請求項9に記載の方法。
  12. 請求項9〜11のいずれかに記載の方法で得られる医薬組成物。
JP2007504378A 2004-03-22 2005-03-18 4−ヒドロキシタモキシフェンの化学的に安定な組成物 Active JP5489407B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/805,530 US20050208139A1 (en) 2004-03-22 2004-03-22 Chemically stable compositions of 4-hydroxy tamoxifen
US10/805,530 2004-03-22
EP04290762.6 2004-03-22
EP04290762A EP1579857A1 (en) 2004-03-22 2004-03-22 Chemically stable compositions of 4-hydroxy tamoxifen
PCT/EP2005/003455 WO2005092310A2 (en) 2004-03-22 2005-03-18 Chemically stable compositions of 4-hydroxy tamoxifen

Publications (3)

Publication Number Publication Date
JP2007530498A JP2007530498A (ja) 2007-11-01
JP2007530498A5 true JP2007530498A5 (ja) 2008-05-08
JP5489407B2 JP5489407B2 (ja) 2014-05-14

Family

ID=34854723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007504378A Active JP5489407B2 (ja) 2004-03-22 2005-03-18 4−ヒドロキシタモキシフェンの化学的に安定な組成物

Country Status (22)

Country Link
US (1) US20050208139A1 (ja)
EP (4) EP1579857A1 (ja)
JP (1) JP5489407B2 (ja)
CN (1) CN101080222B (ja)
AR (1) AR048587A1 (ja)
AT (1) ATE453387T1 (ja)
AU (1) AU2005227073B2 (ja)
CA (1) CA2557806C (ja)
DE (1) DE602005018613D1 (ja)
DK (1) DK1727532T3 (ja)
ES (3) ES2517894T3 (ja)
HK (2) HK1098674A1 (ja)
IL (2) IL177778A (ja)
MX (1) MXPA06010928A (ja)
NO (1) NO337298B1 (ja)
NZ (1) NZ549664A (ja)
PL (1) PL1727532T3 (ja)
PT (1) PT1727532E (ja)
RU (1) RU2389483C2 (ja)
TW (1) TWI401078B (ja)
WO (1) WO2005092310A2 (ja)
ZA (1) ZA200607291B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60305068T2 (de) 2002-12-18 2007-01-11 Laboratoires Besins International Behandlung von mastalgie mit 4-hydroxy-tamoxifen
EP2050443B1 (en) * 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
EP1941871B1 (en) 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
CA2775266C (en) * 2009-10-13 2013-12-31 Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania Anti-cancer tamoxifen-melatonin hybrid ligand
US10016370B2 (en) * 2011-07-14 2018-07-10 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US5475851A (en) * 1986-04-14 1995-12-12 National Instruments Corporation Method and apparatus for improved local and global variable capabilities in a graphical data flow program
US5002938A (en) * 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
CA2032695A1 (en) 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5809266A (en) * 1994-07-29 1998-09-15 Oracle Corporation Method and apparatus for generating reports using declarative tools
DE4435784C2 (de) * 1994-10-06 1998-10-29 Heraeus Electro Nite Int Elektrisch beheizbarer Starterkat
US5777621A (en) * 1994-12-22 1998-07-07 Apple Computer, Inc. Quality control mechanism for three-dimensional graphics rendering
CA2243330A1 (en) * 1996-01-20 1997-07-24 Ioana Popa Tamoxifen and analogues thereof
DE59703511D1 (de) * 1996-03-29 2001-06-13 S W Patentverwaltungs Ges M B Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite"
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
AU2513899A (en) * 1997-12-23 1999-07-19 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
JP2000038335A (ja) * 1998-07-22 2000-02-08 Kanebo Ltd 皮膚化粧料
EP1212325A2 (en) 1999-08-23 2002-06-12 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) * 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
PT1317921E (pt) * 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
US6695171B2 (en) * 2002-02-12 2004-02-24 Seaquistperfect Dispensing Foreign, Inc. Pump dispenser
EP2050443B1 (en) * 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
DE60305068T2 (de) * 2002-12-18 2007-01-11 Laboratoires Besins International Behandlung von mastalgie mit 4-hydroxy-tamoxifen
EP1941871B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) * 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005058297A1 (en) * 2003-12-15 2005-06-30 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Similar Documents

Publication Publication Date Title
JP2007530498A5 (ja)
JP7187522B2 (ja) 勃起不全および他の適応症の処置
Barkin Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome
Egorova et al. Cytotoxic activity of salicylic acid-containing drug models with ionic and covalent binding
Liu et al. Protective effects of quercetin against pyrazinamide induced hepatotoxicity via a cocrystallization strategy of complementary advantages
BRPI0610180A2 (pt) métodos para prevenir, para tratar, e para tratar ou controlar uma condição associada à inflamação
TW200815045A (en) Pharmaceutical compositions of ropinirole and methods of use thereof
IL215897A (en) Pharmacological preparation in equilibrium containing 4-hydroxy tamoxifen and a method for its preparation
TW201247613A (en) Ester derivatives of bimatoprost compositions and methods
Lather et al. Proniosomal gel-mediated transdermal delivery of bromocriptine: in vitro and ex vivo evaluation
JP2019526631A5 (ja)
Täuber et al. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model
JP2010519288A5 (ja)
BRPI0618273A2 (pt) formulações de dosagem oral de ibuprofeno organolepticamente aceitáveis, métodos de produção e uso das mesmas
US20110229535A1 (en) Composition having a sirtuin activator
BR112015018798B1 (pt) Composição antifúngica tópica para tratar onocomicose
CN106470677A (zh) 用于治疗皮肤学疾病及病症的组成物
JP2009535366A5 (ja)
US20220226310A1 (en) Bio-Based Medicines and Methods of Increasing Patient Compliance
JP5608331B2 (ja) 熱産生タンパク質発現促進剤
Hascicek et al. Preparation and evaluation of different gel formulations for transdermal delivery of meloxicam
JP2007535505A5 (ja)
JP2003206239A (ja) 温感組成物及び外用剤組成物
JP5457005B2 (ja) 外用鎮痛組成物
KR20180098104A (ko) 에틸 페룰레이트를 유효성분으로 포함하는 알러지 완화용 조성물